-
Aclaris Therapeutics Submits IND for RA Treatment
contractpharma
June 14, 2019
If the IND is allowed by the FDA, Aclaris plans to initiate a Phase 1 trial of ATI-450, an oral MK2 inhibitor in 2H19
-
Amyloidosis treatment discontinued from clinical trials
europeanpharmaceuticalreview
June 11, 2019
A treatment for amyloidosis has been pulled from clinical trials after failing to reach endpoints.
-
FDA Approves Treatment for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia
americanpharmaceuticalreview
June 06, 2019
The U.S. Food and Drug Administration (FDA) approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP
-
FDA Approves First Treatment for Episodic Cluster Headache to Reduce Frequency
americanpharmaceuticalreview
June 06, 2019
The U.S. Food and Drug Administration (FDA) approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults.
-
Few Prostate Cancer Patients Are Getting Checkups They Need
drugs
June 06, 2019
Few Prostate Cancer Patients Are Getting Checkups They Need.
-
'Secret Shopper' Study Finds Many Who Need Addiction Treatment Can't Get It
drugs
June 05, 2019
When people who are addicted to opioids make the difficult decision to quit, the last thing they need to face are barriers to treatment.
-
Esketamine Nasal Spray May Improve Refractory Depression Outcomes
drugs
June 03, 2019
Esketamine Nasal Spray May Improve Refractory Depression Outcomes.
-
Noncompliance Common in Teens Prescribed STI Treatment in ED
drugs
June 03, 2019
Noncompliance Common in Teens Prescribed STI Treatment in ED.
-
A New Way to Fight a Previously 'Inoperable' Pancreatic Cancer
drugs
May 31, 2019
A New Way to Fight a Previously 'Inoperable' Pancreatic Cancer.
-
FDA Approves Jakafi (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease
drugs
May 29, 2019
Incyte Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi (ruxolitinib) for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older.